Company news
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) news
Zevra Therapeutics, Inc. news releases on 6ix. Latest, Sep 2, 2026: Zevra Therapeutics to Present at Upcoming Investor Conferences
Press releases & updates
Zevra Therapeutics to Present at Upcoming Investor Conferences
September 2, 2026
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
August 25, 2026
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
August 5, 2026
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
August 4, 2026
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
August 3, 2026
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
July 24, 2026
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
July 22, 2026
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
June 23, 2026
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
June 11, 2026
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
June 8, 2026
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
May 12, 2026
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
May 6, 2026
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
April 21, 2026
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer under Nasdaq Listing Rule 5635(4)
March 23, 2026
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
March 19, 2026
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
March 15, 2026
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
March 9, 2026
Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
March 8, 2026
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
March 4, 2026
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
March 2, 2026
Zevra Therapeutics to Present at the Citizens Life Sciences Conference
February 25, 2026
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
February 4, 2026
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
February 2, 2026
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
January 26, 2026
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
January 8, 2026
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C
December 30, 2025
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)
December 28, 2025
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 11, 2025
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
December 1, 2025
Zevra Therapeutics, Inc. Announces CFO Transition
November 19, 2025
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
November 4, 2025
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
October 28, 2025
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
October 26, 2025
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)
September 18, 2025
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylb...
September 17, 2025
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
September 3, 2025
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
August 27, 2025
Zevra Therapeutics to Participate at Upcoming Investor Conferences in September
August 25, 2025
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update
August 11, 2025
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 5, 2025
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
August 3, 2025
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
July 27, 2025
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
July 17, 2025
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
July 15, 2025
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
July 10, 2025
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
May 28, 2025
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees
May 20, 2025
Zevra Reports First Quarter 2025 Financial Results and Corporate Update
May 12, 2025
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
May 5, 2025
Zevra Therapeutics to Participate in the Citizens Life Science Conference
April 30, 2025